It was another busy week for the IPO market as 15 new issuers went public, with Rivian (RIVN) in the spotlight. The pre-revenue electric truck developer became the largest IPO of 2021, raising nearly $12 billion in the largest IPO since...read more
Vaxxinity, a Phase 2 biotech developing vaccine therapies for chronic diseases using synthetic peptides, raised $78 million by offering 6 million shares at $13, below the range of $14 to $16. The company offered 0.7 million fewer shares than anticipated. ...read more
The IPO market is expected to stay busy with 11 IPOs schedule to raise $10.2 billion in the week ahead. Electric truck developer Rivian Automotive (RIVN) plans to raise $8.0 billion at a $57.1 billion market cap. This founder-led...read more
Vaxxinity, a Phase 2 biotech developing vaccine therapies for chronic diseases using synthetic peptides, announced terms for its IPO on Friday. The Dallas, TX-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to...read more
US IPO Weekly Recap: Rivian completes the largest deal since Alibaba in a 15 IPO week
It was another busy week for the IPO market as 15 new issuers went public, with Rivian (RIVN) in the spotlight. The pre-revenue electric truck developer became the largest IPO of 2021, raising nearly $12 billion in the largest IPO since...read more
Vaccine biotech Vaxxinity prices downsized IPO at $13, below the range
Vaxxinity, a Phase 2 biotech developing vaccine therapies for chronic diseases using synthetic peptides, raised $78 million by offering 6 million shares at $13, below the range of $14 to $16. The company offered 0.7 million fewer shares than anticipated. ...read more
US IPO Week Ahead: The IPO market revs its engine in an 11 IPO week
The IPO market is expected to stay busy with 11 IPOs schedule to raise $10.2 billion in the week ahead. Electric truck developer Rivian Automotive (RIVN) plans to raise $8.0 billion at a $57.1 billion market cap. This founder-led...read more
Vaccine biotech Vaxxinity sets terms for $101 million IPO
Vaxxinity, a Phase 2 biotech developing vaccine therapies for chronic diseases using synthetic peptides, announced terms for its IPO on Friday. The Dallas, TX-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to...read more